DEVELOPMENT OF DOSAGE FORMS AND DELIVERY SYSTEMS FOR ANTITUMOR AGENTS Release Date: December 12, 2001 NOTICE: NOT-CA-02-008 National Cancer Institute The Pharmaceutical Resources Branch of the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (PRB/DTP/DCTD/NCI) is seeking contractors to develop acceptable dosage forms for compounds to be subsequently evaluated in cancer patients. NCI will select and provide the compounds to be studied. In addition to solubility studies, the projects may require analytical work, particularly the development of a stability-indicating assay to monitor the integrity of the parent compound during the formulation studies. These investigations will be directed toward a pharmaceutical dosage form that will meet certain solubility and stability targets determined by the Government. Data will be submitted to the Project Officer primarily in the form of progress reports but additional reports may be required. The Contractor will be required to maintain laboratory notebooks containing raw data at the contract site. The data will remain at the contract site but copies may be requested at the discretion of the Government. The Contractors may be assigned compounds covered by a discreet agreement. Therefore, the contract will contain the current confidentiality clause in accordance with HHSAR 352-224-70. The Principal Investigator on this project should possess a Ph.D. in Pharmaceutics or Medicinal Chemistry and should also have at least three years experience in the development of injectable formulations. It is anticipated that three (3) cost-reimbursement term (level of effort) type contracts will be awarded for five (5) years. The proposed contract project represents a re-competition of the following contracts: NO1-CM-77109 (University of Arizona), NO1-CM-77017 (University of Kansas), and NO1-CM-77108 (University of Utah). All responsible offerors will be considered. The solicitation is scheduled for electronic release on December 6, 2001. The RFP may be accessed through the Research Contracts Branch Home Page by using the following Internet address: http://rcb.nci.nih.gov/. It's the offeror's responsibility to monitor the above Internet site for the release of this solicitation and amendments, if any. INQUIRIES For further information contact: Diane H. Stalder Contract Specialist Treatment, Biology and Sciences Section, RCB National Cancer Institute Executive Plaza South 6120 EXECUTIVE BLVD MSC 7220 Bethesda, MD 20892-7220 e-mail: ds88b@nih.gov voice: (301) 435-3822 fax: (301) 402-6699
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |